The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases
暂无分享,去创建一个
R. Semrau | M. Eble | M. Duma | G. Hildebrandt | T. Brunner | J. Boda-Heggemann | S. Gerum | D. Imhoff | O. Blanck | M. Guckenberger | R. Krempien | F. Lohaus | A. Wittig | R. Klement | C. Petersen | D. Habermehl | C. Ostheimer | H. Alheid | G. Becker | V. Lewitzki | A. Papachristofilou | T. Schneider | S. Wachter | C. Henkenberens | P. Hass | S. Adebahr | I. Ernst | J. Rieber | H. Kahl | N. D. Klass | E. Schrade | M. Allgaeuer | N. Abbasi-Senger | N. Andratschke
[1] T. Treasure,et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .
[2] R. Klement. Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] R. Semrau,et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] M. Eble,et al. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[6] Henry Knipe,et al. Oligometastases , 2016, Radiopaedia.org.
[7] S. Eschrich,et al. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.
[8] L. Uhlmann,et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". , 2016, Lung cancer.
[9] D. Rades,et al. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases , 2016, Radiation oncology.
[10] Kyu Ha Lee,et al. Semi-Competing Risks Data Analysis: Accounting for Death as a Competing Risk When the Outcome of Interest Is Nonterminal , 2016, Circulation. Cardiovascular quality and outcomes.
[11] M. Duma,et al. Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. , 2016, International Journal of Radiation Oncology, Biology, Physics.
[12] Ahmedin Jemal,et al. Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.
[13] SebastienHaneuse,et al. Semi-Competing Risks Data Analysis , 2016 .
[14] Virginie Rondeau,et al. A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer , 2015, Statistical methods in medical research.
[15] S. Eschrich,et al. Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. , 2014, International journal of radiation oncology, biology, physics.
[16] I. Poon,et al. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).
[17] A. Viste,et al. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival , 2014, World Journal of Surgical Oncology.
[18] Deepinder P. Singh,et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. , 2014, Journal of thoracic disease.
[19] J. Shindoh,et al. Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases , 2012, Annals of surgery.
[20] P. Okunieff,et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.
[21] R. Weichselbaum,et al. Stereotactic body radiotherapy for multisite extracranial oligometastases , 2012, Cancer.
[22] Virginie Rondeau,et al. frailtypack: An R Package for the Analysis of Correlated Survival Data with Frailty Models Using Penalized Likelihood Estimation or Parametrical Estimation , 2012 .
[23] Stef van Buuren,et al. MICE: Multivariate Imputation by Chained Equations in R , 2011 .
[24] E. Kunieda,et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] F. Petrella,et al. A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases” , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] E. Steyerberg,et al. [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.
[27] Jinfeng Xu,et al. Statistical Analysis of Illness–Death Processes and Semicompeting Risks Data , 2010, Biometrics.
[28] V. Heinemann,et al. Radiosurgery of Liver Tumors: Value of Robotic Radiosurgical Device to Treat Liver Tumors , 2010, Annals of Surgical Oncology.
[29] L. Gaspar,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W. Franklin,et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Weichselbaum,et al. A rationale for the targeted treatment of oligometastases with radiotherapy , 2008, Journal of surgical oncology.
[32] A. Gelman. Scaling regression inputs by dividing by two standard deviations , 2008, Statistics in medicine.
[33] Paul Janssen,et al. Frailty Model , 2007, International Encyclopedia of Statistical Science.
[34] Jon Williamson,et al. Interpreting Causality in the Health Sciences , 2007 .
[35] M. Schell,et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. , 2007, International journal of radiation oncology, biology, physics.
[36] U. Haedinger,et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases , 2006, Acta oncologica.
[37] Abraham Philip,et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases , 2006, Acta oncologica.
[38] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[39] L H Blumgart,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.
[40] O. Salazar. Colorectal Cancer: Metastatic Patterns and Prognosis , 1993, Southern medical journal.